Comparative Pharmacology
Head-to-head clinical analysis: DAYSEE versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYSEE versus PHILITH.
DAYSEE vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.
1 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 18-36 hours), supporting once-daily dosing for steady state within 5 days.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal 70% (metabolites), biliary/fecal 30% (parent drug and metabolites). No active drug excreted unchanged.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive